BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 18662289)

  • 1. Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine.
    Hawwa AF; Millership JS; Collier PS; Vandenbroeck K; McCarthy A; Dempsey S; Cairns C; Collins J; Rodgers C; McElnay JC
    Br J Clin Pharmacol; 2008 Oct; 66(4):517-28. PubMed ID: 18662289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate.
    Pettersson B; Almer S; Albertioni F; Söderhäll S; Peterson C
    Ther Drug Monit; 2002 Jun; 24(3):351-8. PubMed ID: 12021625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
    Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
    Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
    Moon W; Loftus EV
    Aliment Pharmacol Ther; 2016 Apr; 43(8):863-883. PubMed ID: 26876431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key factors associated with 6-thioguanine and 6-methylmercaptopurine nucleotide concentrations in children treated by thiopurine for acute leukaemia and inflammatory bowel disease.
    de Beaumais TA; Lorrain S; Mamhoudi N; Simonin M; Martinez Vinson C; Medard Y; Petit A; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2024 Jan; 90(1):209-219. PubMed ID: 37621013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity.
    Lennard L; Welch JC; Lilleyman JS
    Br J Clin Pharmacol; 1997 Nov; 44(5):455-61. PubMed ID: 9384462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deletion of glutathione-s-transferase m1 reduces azathioprine metabolite concentrations in young patients with inflammatory bowel disease.
    Stocco G; Cuzzoni E; De Iudicibus S; Franca R; Favretto D; Malusà N; Londero M; Cont G; Bartoli F; Martelossi S; Ventura A; Decorti G
    J Clin Gastroenterol; 2014 Jan; 48(1):43-51. PubMed ID: 23787247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
    Azimi F; Mortazavi Y; Alavi S; Khalili M; Ramazani A
    Leuk Res; 2015 Oct; 39(10):1048-54. PubMed ID: 26242828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations.
    Al Hadithy AF; de Boer NK; Derijks LJ; Escher JC; Mulder CJ; Brouwers JR
    Dig Liver Dis; 2005 Apr; 37(4):282-97. PubMed ID: 15788214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
    Gisbert JP; González-Lama Y; Maté J
    Gastroenterol Hepatol; 2006 Nov; 29(9):568-83. PubMed ID: 17129552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy.
    Adam de Beaumais T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2011 Apr; 71(4):575-84. PubMed ID: 21395650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.
    Chouchana L; Narjoz C; Beaune P; Loriot MA; Roblin X
    Aliment Pharmacol Ther; 2012 Jan; 35(1):15-36. PubMed ID: 22050052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
    Hawwa AF; Collier PS; Millership JS; McCarthy A; Dempsey S; Cairns C; McElnay JC
    Br J Clin Pharmacol; 2008 Dec; 66(6):826-37. PubMed ID: 18823306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations.
    Lancaster DL; Lennard L; Rowland K; Vora AJ; Lilleyman JS
    Br J Haematol; 1998 Jul; 102(2):439-43. PubMed ID: 9695957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease.
    Cuffari C; Dassopoulos T; Turnbough L; Thompson RE; Bayless TM
    Clin Gastroenterol Hepatol; 2004 May; 2(5):410-7. PubMed ID: 15118980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.